Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2018

View Archived Issues

Fighting senescence boosts immunity

MANF rescues dopaminergic neurons in C. elegans alpha-synuclein models of Parkinson's disease

TAS-05567 selectively inhibits Syk kinase: potential treatment for autoimmune and allergic diseases

Immunity is for babies

SOM Biotech initiates phase IIa trial of repurposed drug

THX-160 shows promise in preclinical studies for acute and chronic pain

Selective PDE4D PET ligands developed to study depression and cognitive impairment

Orion Biotechnology earns grant to support development of microbicide candidate

Researchers unveil new biomarkers of treatment-free survival in CLL

Favorable review of safety data from second dose cohort in MAGE-A10 SPEAR T-cell study

Takeda and Ovid announce expansion of the clinical program for TAK-935

Topline data presented from phase III trial of tanezumab

Positive interim data presented from a phase II/III study of marzeptacog alfa

Beta cells make and secrete autoimmune peptides

Chinese phase III trial of GV-971 in Alzheimer's disease meets primary endpoint

RPL28 gene polymorphism tied to reduced survival in FOLFIRI-treated mCRC patients

KDDF grant will support evaluation of Hyleukin-7 with Keytruda in triple-negative breast cancer

Incyte studies INCB-054707 for hidradenitis suppurativa in phase II trial

Vyriad collaborates with Merck KGaA and Pfizer to study Voyager-V1 with avelumab

FDA approves Kisqali for HR-positive HER-negative advanced or metastatic breast cancer

Phase III study of subcutaneous vedolizumab in ulcerative colitis meets primary endpoint

Daiichi Sankyo and collaborator patent TNSALP inhibitors

Aquinnah Pharmaceuticals divulges TDP-43 aggregation inhibitors

Nampt inhibition with OT-82 shows promise in xenograft leukemia models

Incyte presents PD-1/PD-L1 interaction inhibitors

Global Blood Therapeutics patents EHMT2 inhibitors

Kissei Pharmaceutical synthesizes new TRPM8 antagonists

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...